broadwww.gogo.com

www.gogo.com  时间:2021-03-20  阅读:()
EditorialTheEUGOGOConsensusStatementontheManagementofGraves'Orbitopathy:EquallyApplicabletoNorthAmericanCliniciansandPatientsTheEuropeangrouponGraves'orbitopathy(EUGOGO;www.
eugogo.
org)isamultidisciplinaryconsortiumofclinicianscommittedtoimprovingtheman-agementofpatientswiththeocularcomplicationsofGraves'disease.
ThegroupdevelopedaconsensusstatementonthemanagementofGraves'orbitopathy(GO)thatwasunveiledattheannualmeetingoftheEuropeanThyroidAssociationinLeipzig,Germany,inSeptember2007,andsimultane-ouslyappearsinthisissueofThyroidandintheEuropeanJournalofEndocrinology(1).
EUGOGOistobecommendedfortheireffortsthatreectaremarkabledegreeofinterna-tionalcooperationbyacademicendocrinologistsandoph-thalmologists.
Theauthorsrefertothedocumentasa''consensusstate-ment''byexpertsintheeld,ratherthanapracticeguideline.
Thisseemsappropriate,becausewhiletheEUGOGOgroupcanbecreditedwithhavingperformedthemajorityofran-domizedcontrolledtrials(RCTs)inthisarea,theyarenotofsufcientscopetosupportformalpracticeguidelines.
De-spitethis,thedocumentistimelyandshouldproveusefultoclinicianswhomanageGOpatients.
Theauthorsrightlyanticipatethatthedocumentwill''provideafocusforauditandresearch''andaidintheidenticationoftopicsforfutureRCTs.
Theconsensusstatementisscholarlyandconcise,andtherecommendationsaregenerallyapplicabletoNorthAmeri-can,aswellasEuropean,cliniciansandpatients.
Thegradedrecommendationsareappendedinthedocument,andtheevidencesupportingeachisdiscussedindetailinthebodyofthetext.
TheapplicationoftherecommendationsrequiresthatcliniciansmustrstsegregatetheirGOpatientsinto''mild,''''moderatetosevere,''or''sight-threatening''categories,anddeterminewhetherornotthediseaseisactive.
Sufcientde-tailsareprovidedwithinthetextregardingtheassessmentofdiseaseseverityandactivitytoallowclassicationintothesebroadcategories.
EUGOGOdoesnotadvocateusinganyde-tailedgradingorscoringsystemotherthantherelativelysimple''clinicalactivityscore''andspecicocularmeasure-mentstoassesstheseverityofthedisease.
Whilethisapproachmaynotideallycaptureallfeaturesofthedisease,ithasbeenvalidatedbythegroupinnumerousclinicalstudiesandshouldserveasthegoldstandardagainstwhichotherGOclassica-tionsystemsaremeasured.
ThedocumentwillserveasanespeciallyusefultoolforclinicianswhoalreadyhavesomeexpertiseinmanagingGOpatients.
OthersnotsoexperiencedbutencounterGOpa-tientsintheirpracticeareadvisedto''referpatientswithGO,exceptforthemildestcases,tocombinedthyroid–eyeclinicsforfurtherassessmentandmanagement.
''Whichreferralsshouldbemadeurgentlyandwhicharenonurgentiscare-fullyoutlinedinthetext.
TheproblematicaspectofthisrecommendationforcliniciansinNorthAmerica,however,isthatregionalGOconsultantsarefrequentlyophthalmolo-gistswhodonotworkincombinedthyroid–eyeclinics.
OneofthemanypositiveresultsstemmingfromtheinceptionofEUGOGOhasbeenthemandatoryestablishmentofacom-binedthyroid–eyeclinicwithineachoftheEuropeanmedicalcenterwishingtoparticipateintheconsortium.
OnlythroughthistypeofcooperationcanGOpatientsbenetfromthefullrangeofexpertiseneededtounderstandandmanageallaspectsofthisperplexingdisease.
Whilethevastmajorityoftherecommendationsseemtometobequitereasonableandbasedtotheextentpossibleonpertinentliterature,Idotakeissuewiththestatementthat''thetreatmentofchoiceformoderatetosevereandactiveGOispulsesofintravenousglucocorticoids(GCs).
''WhilesevereGOmaywarrantthisapproach,IremainreluctanttorecommendivGCstopatientswithonlymoderatedisease(i.
e.
,thosehavingonlyasinglefeaturethatwouldplacetheminthe''moderatetosevere''category,orafewfeaturesmeasuringjustabovemild).
MyconcernstemsbothfromreportsoffatalacuteliverfailureinfourGOpatientsduringorfollowingcompletionofivGCtreatment(2,3),andfromthenaturalhistoryofthediseaseshowingimprovementinthemajorityof(albeitunselected)patientswithinayears'time.
Fortunately,thefrequencyofhepatotoxicityappearstobeverylow;7ofapproximately800GOpatientstreatedinItalywithivGCssufferedsevereliverdamage,ofwhom3died(3).
BecausenocaseofliverfailurehasbeenreportedinGOpatientsreceiving<8gmethylprednisolone,thecon-sensusstatementindicatesthatthecumulativedoseinonecourseshouldbelessthanthisamountandspeciesthativGCsshouldonlybeadministeredincentersexperiencedinthistherapy.
Despitethis,therisk–benetratioforivGCsinpatientswithactivediseaseofonlymoderateseveritywhomightdoequallywellwithoralsteroidsorevencarefulTHYROIDVolume18,Number3,2008MaryAnnLiebert,Inc.
DOI:10.
1089=thy.
2008.
0034281observationandfrequentreassessmentseemstometobeweightedtowardthesideofunacceptablerisk.
Insummary,theconsensusstatementbyEUGOGOisatimelyandusefuldocumentthatcanbeupdatedasadditio-nalevidencefromfutureRCTsbecomesavailable.
TheEu-ropeangroupisproceedingwithmulticentertrialsthatwillallowrecruitmentoflargenumbersofpatientsintothesestudies.
Thisconsensusstatementbringstotheforeashort-cominginthecareofGOpatientsintheUnitedStates,namely,thatmanypatientsarenotcaredforinjointthyroid–eyeclinics.
Inaddition,endocrinologists,ophthalmologists,andotherswhoseeGOpatientsinthiscountryarenotyetorganizedtoperformmulticenterRCTs.
Thereis,how-ever,activityunderwaytoincreasecooperationbetweenthesegroupsandtoestablishtheimportantinfrastructureneededtoperformlargemulticenterGOtrialsinNorthAmerica.
Finally,whileevidence-basedguidelinesorconsensusstatementscanfacilitatedecisionmaking,managementmustbeultimatelyindividualizedandfocusedontheneedsanddesiresofthepatient.
Thisrequirestheapplicationofboththeartandscienceofmedicine,anddemandsthatthecli-nicianactivelylistenstoGOpatients,manyofwhomareunderstandablyapprehensiveandfrightened.
Compassio-natecounselingofpatientshouldincludewiderangingdis-cussionsonthenatureoftheconditionanditsnaturalhistory,aswellascustomizedtreatmentoptions.
Suchanapproachislikelytoimproveoutcomesofwhatisoftenahighlydistressingdisease.
References1.
BartalenaL,BaldeschiL,DickensonA,EcksteinA,Kendall-TaylorP,MarcocciC,etal.
2007ConsensusstatementoftheEuropeanGrouponGraves'Orbitopathy(EUGOGO)onthemanagementofGraves'orbitopathy.
Thyroid18:333–346.
2.
WeisselM,HauffW2000Acuteandfatalliverfailureafterhigh-doseglucocorticoidpulsetherapyinapatientswithsevereeyedisease.
Thyroid10:521.
3.
MarinoM,MorabitoBrunetteMR,BartalenaL,PincheraA,MarcocciC2004AcuteandsevereliverdamageassociatedwithintravenousglucocorticoidpulsetherapyinpatientswithGraves'ophthalmopathy.
Thyroid14:403–406.
—RebeccaBahn,M.
D.
President,AmericanThyroidAssociationConsultantinEndocrinology,MayoClinic282BAHN

6元虚拟主机是否值得购买

6元虚拟主机是否值得购买?近期各商家都纷纷推出了优质便宜的虚拟主机产品,其中不少6元的虚拟主机,这种主机是否值得购买,下面我们一起来看看。1、百度云6元体验三个月(活动时间有限抓紧体验)体验地址:https://cloud.baidu.com/campaign/experience/index.html?from=bchPromotion20182、Ucloud 10元云主机体验地址:https:...

月神科技 国内上新成都高防 全场八折促销续费同价!

月神科技是由江西月神科技有限公司运营的一家自营云产品的IDC服务商,提供香港安畅、香港沙田、美国CERA、成都电信等机房资源,月神科技有自己的用户群和拥有创宇认证,并且也有电商企业将业务架设在月神科技的平台上。本次带来的是全场八折促销,续费同价。并且上新了国内成都高防服务器,单机100G集群1.2T真实防御,上层屏蔽UDP,可定制CC策略。非常适合网站用户。官方网站:https://www.ysi...

火数云-618限时活动,国内云服务器大连3折,限量50台,九江7折 限量30台!

官方网站:点击访问火数云活动官网活动方案:CPU内存硬盘带宽流量架构IP机房价格购买地址4核4G50G 高效云盘20Mbps独享不限openstack1个九江287元/月立即抢购4核8G50G 高效云盘20Mbps独享不限openstack1个九江329元/月立即抢购2核2G50G 高效云盘5Mbps独享不限openstack1个大连15.9元/月立即抢购2核4G50G 高效云盘5Mbps独享不限...

www.gogo.com为你推荐
李子柒年入1.6亿宋朝鼎盛时期 政府财政收入有将近1亿贯铜钱,那么GDP是多少呢?甲骨文不满赔偿不签合同不满一年怎么补偿同ip网站查询怎样查询一个ip绑了多少域名18comic.fun有什么好玩的网站www.119mm.comwww.993mm+com精品集!百度指数词什么是百度指数百度指数词百度指数我创建的新词www.mywife.ccMywife-No 00357 MANAMI SAITO种子下载地址有么?求好心人给www.hyyan.com请问我是HY了吗?在线等www.zhiboba.com网上看nba
什么是虚拟主机 高防直连vps 域名备案号查询 godaddy域名解析教程 日志分析软件 服务器cpu性能排行 dropbox网盘 debian7 云图标 建站代码 镇江联通宽带 godaddy域名证书 申请个人网站 上海服务器 德隆中文网 photobucket 镇江高防 创速 国外代理服务器 wordpress空间 更多